All Outputs (2)

Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study (2021)
Journal Article
Persson, M. S., Harman, K. E., Thomas, K. S., Chalmers, J. R., Vinogradova, Y., Langan, S. M., …Gran, S. (2021). Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study. British Journal of General Practice, 71(713), e904-e911. https://doi.org/10.3399/BJGP.2020.0870

Background: Oral prednisolone is the mainstay treatment for bullous pemphigoid, an autoimmune blistering skin disorder affecting older people. Treatment with moderate-to-high doses is often initiated in secondary care, but then continued in primary c... Read More about Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study.

Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England (2021)
Journal Article
Persson, M., Harman, K., Thomas, K., Chalmers, J., Vinogradova, Y., Langan, S., …Gran, S. (2021). Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England. BMC Medical Research Methodology, 21(1), Article 22. https://doi.org/10.1186/s12874-021-01212-1

Background Trials of novel agents are required to improve the care of patients with rare diseases, but trial feasibility may be uncertain due to concerns over insufficient patient numbers. We aimed to determine the size of the pool of potential part... Read More about Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England.